With Lumoxiti confirmed as commercially unviable monalizumab fails its phase 3 trial in head and neck cancer.
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Gilead opts in at long last, and that’s more than many might have been expecting.
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.